Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Interleukin 10 (IL-10) cytokine protein  - looks like a red ribbon

Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University’s Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD). This discovery reshapes understanding of IBD and opens the way to targeted approaches to diagnosis and treatment in a subset of patients. The findings suggest that inflammatory bowel disease is not a single condition, but a group of biologically distinct diseases driven by different underlying mechanisms.

In a study published in the New England Journal of Medicine, researchers analysed over 4,900 patients with IBD and made two major discoveries: first, that a substantial subset of patients show autoimmune responses to one of the guardians of the immune system, interleukin-10 (IL-10), which leads to uncontrolled inflammation; and second, that this damaging immune response is the mechanism for one of the strongest known genetic risk factors for IBD.

Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body’s key controls on inflammation, effectively remove the immune system’s natural ‘brake’ on inflammation, allowing inflammatory responses to continue unchecked.

IBD, which includes Crohn’s disease and ulcerative colitis, affects around 500,000 people in the UK and millions worldwide. It is a lifelong condition that commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication and, in some cases, surgery. Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control – impacting their lives and costing the health care system millions. 

Read the full story on the Nuffield Department of Medicine website.

Similar stories

ARIA gives major boost to Oxford researchers using AI scientists to accelerate cancer vaccine discovery and development

The Advanced Research + Invention Agency (ARIA) has today announced that it is committing an additional £8m of funding to the pioneering UK Cancer Vaccine AI Scientist & Supercomputing Project at the University of Oxford. The funding will enable the research team to extend its AI cancer immunology platform towards patients, bringing together human oncology experts, AI models of tumour-immune recognition, automated laboratory experimentation, Sovereign UK AI supercomputing, personalised vaccine manufacturing and clinical testing.

New review highlights advances and challenges in studying antigen-specific T cells

A new review published in Nature Reviews Immunology by Professor Tao Dong's group at the CAMS Oxford Institute and the MRC Translational Immune Discovery Unit highlights recent advances and remaining challenges in studying antigen-specific T cells - rare immune cells that recognise viruses, bacteria, tumours and self-antigens, and play central roles in protective immunity and autoimmune disease.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Oxford Population Health researchers to tackle one of cancer’s toughest challenges

Oxford researchers join $25m international effort to uncover immune mechanisms that protect certain people from cancer.

New Oxford-led trial explores if the immune system can be trained to control HIV

Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.

Rapamycin helps protect immune cells against DNA damage

New research carried out by Dr Loren Kell at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) has demonstrated for the first time that rapamycin can reduce DNA damage in immune cells, a hallmark of ageing.

Similar stories

ARIA gives major boost to Oxford researchers using AI scientists to accelerate cancer vaccine discovery and development

The Advanced Research + Invention Agency (ARIA) has today announced that it is committing an additional £8m of funding to the pioneering UK Cancer Vaccine AI Scientist & Supercomputing Project at the University of Oxford. The funding will enable the research team to extend its AI cancer immunology platform towards patients, bringing together human oncology experts, AI models of tumour-immune recognition, automated laboratory experimentation, Sovereign UK AI supercomputing, personalised vaccine manufacturing and clinical testing.

New review highlights advances and challenges in studying antigen-specific T cells

A new review published in Nature Reviews Immunology by Professor Tao Dong's group at the CAMS Oxford Institute and the MRC Translational Immune Discovery Unit highlights recent advances and remaining challenges in studying antigen-specific T cells - rare immune cells that recognise viruses, bacteria, tumours and self-antigens, and play central roles in protective immunity and autoimmune disease.

Oxford researchers awarded ARIA funding to develop transformative anti-viral therapies

Three innovative research projects aimed at transforming how we protect against respiratory viruses, led by teams at the University of Oxford, have secured funding through the UK’s Advanced Research and Invention Agency (ARIA).

Oxford Population Health researchers to tackle one of cancer’s toughest challenges

Oxford researchers join $25m international effort to uncover immune mechanisms that protect certain people from cancer.

New Oxford-led trial explores if the immune system can be trained to control HIV

Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.

Rapamycin helps protect immune cells against DNA damage

New research carried out by Dr Loren Kell at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) has demonstrated for the first time that rapamycin can reduce DNA damage in immune cells, a hallmark of ageing.